Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years Lantern Pharma Inc. (NASDAQ: LTRN), an ...
Japanese patient cohort enrollment is completed ahead of schedule at multiple clinical sites including the National Cancer Center in Tokyo The incidence rate of never-smokers with non-small cell lung ...
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback